Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Varsha Iyer

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Clinical Pharmacology in Drug Development|October 25, 2024
Relative Bioavailability Studies With Mitapivat: Formulation and Food Effect Assessments in Healthy SubjectsVarsha Iyer, Karen Sullivan, Yan Yan, et al.
Clinical and Translational Science|August 19, 2023
An innovative phase I study in healthy subjects to determine the mass balance, elimination, metabolism, and absolute bioavailability of mitapivatChandra Prakash, Heidi Mangus, Yan Yan, et al.
Journal of Neurochemistry|June 6, 2006
Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expressionJeffrey M Brown, Shawn Gouty, Varsha Iyer, et al.
British Journal of Pharmacology|December 7, 2005
Differential phosphorylation and dephosphorylation of beta2-adrenoceptor sites Ser262 and Ser355,356Varsha Iyer, Tuan M Tran, Estrella Foster, et al.
Experimental Cell Research|June 8, 2007
Inhibitors of phosphoinositide 3-kinase cause defects in the postendocytic sorting of beta2-adrenergic receptorsHibah O Awwad, Varsha Iyer, Jennifer L Rosenfeld, et al.
Antimicrobial Agents and Chemotherapy|February 9, 2011
Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemiaDavid Andes, Paul G Ambrose, Jeffrey P Hammel, et al.
Investigational New Drugs|August 4, 2018
Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitorJames J Harding, Todd M Bauer, Daniel S W Tan, et al.
Blood|May 16, 2022
A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell diseaseJulia Z Xu, Anna Conrey, Ingrid Frey, et al.
Journal of Medicinal Chemistry|August 24, 2018
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini, et al.
Nature|March 23, 2017
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1Andrew A Wylie, Joseph Schoepfer, Wolfgang Jahnke, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Clinical Pharmacology in Drug Development|October 25, 2024
Relative Bioavailability Studies With Mitapivat: Formulation and Food Effect Assessments in Healthy SubjectsVarsha Iyer, Karen Sullivan, Yan Yan, et al.
Clinical and Translational Science|August 19, 2023
An innovative phase I study in healthy subjects to determine the mass balance, elimination, metabolism, and absolute bioavailability of mitapivatChandra Prakash, Heidi Mangus, Yan Yan, et al.
Journal of Neurochemistry|June 6, 2006
Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN/OFQ expressionJeffrey M Brown, Shawn Gouty, Varsha Iyer, et al.
British Journal of Pharmacology|December 7, 2005
Differential phosphorylation and dephosphorylation of beta2-adrenoceptor sites Ser262 and Ser355,356Varsha Iyer, Tuan M Tran, Estrella Foster, et al.
Experimental Cell Research|June 8, 2007
Inhibitors of phosphoinositide 3-kinase cause defects in the postendocytic sorting of beta2-adrenergic receptorsHibah O Awwad, Varsha Iyer, Jennifer L Rosenfeld, et al.
Antimicrobial Agents and Chemotherapy|February 9, 2011
Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemiaDavid Andes, Paul G Ambrose, Jeffrey P Hammel, et al.
Investigational New Drugs|August 4, 2018
Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitorJames J Harding, Todd M Bauer, Daniel S W Tan, et al.
Blood|May 16, 2022
A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell diseaseJulia Z Xu, Anna Conrey, Ingrid Frey, et al.
Journal of Medicinal Chemistry|August 24, 2018
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini, et al.
Nature|March 23, 2017
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1Andrew A Wylie, Joseph Schoepfer, Wolfgang Jahnke, et al.
Pageof 2